The Bundibugyo Ebola outbreak in the Democratic Republic of the Congo has now killed at least 625 confirmed individuals, with two additional deaths confirmed in Uganda, making it the largest Bundibugyo virus outbreak ever recorded, according to current data cited on the Wikipedia 2026 Ebola epidemic tracking page and corroborated by WHO situation reports.
The outbreak, active since May 2026, prompted the CDC to implement entry restrictions covering travelers from DRC, Uganda, and South Sudan. The most recent 30-day entry restriction order, issued June 21, 2026, is set to expire around July 21 — 11 days from now. The CDC and Department of Homeland Security must decide whether to extend those measures.
No cases of Bundibugyo virus disease have been confirmed in the United States from this outbreak.
Why This Matters
The Bundibugyo virus is one of four known species of Ebola virus. It causes severe hemorrhagic fever with a case fatality rate estimated at approximately 25% to 50% in prior outbreaks. There is no approved vaccine for Bundibugyo virus — the two licensed Ebola vaccines (Ervebo and the Mvabea/Zabdeno regimen) both target the Zaire strain and are not considered effective against Bundibugyo by the WHO, which has recommended against their use in this outbreak.
Treatment is entirely supportive. A clinical trial evaluating two experimental therapies — the monoclonal antibody MBP134 and the antiviral remdesivir — began in DRC on July 2, 2026, according to UN News reporting, with more than 1,200 treatment doses available.
The WHO has underscored that the true scale of this outbreak remains uncertain. WHO Representative to the DRC Dr. Anne Ancia told reporters on July 8: "We would like to say it is stabilising, but frankly, we cannot say it yet." Ongoing armed conflict in the region — particularly in Ituri, North Kivu, and South Kivu provinces — is complicating surveillance, contact tracing, and field hospital access.
What We Know So Far
The outbreak was first confirmed on May 14–15, 2026, in Ituri Province of northeastern DRC, after laboratory analysis identified Bundibugyo virus in samples from two health zones: Mongbwalu and Rwampara. The WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) on May 16 — the eighth PHEIC declaration in the history of modern international health regulations.
As of early July 2026, confirmed case counts in DRC had reached 1,561 confirmed cases with 506 confirmed deaths as reported by the WHO on July 5; the 625 confirmed deaths figure reflects updated data in the second week of July as the outbreak continued to grow. Uganda has confirmed 20 cases and two deaths. One imported case in a medical doctor was also confirmed in France.
Ituri Province remains the epicenter, accounting for the majority of cases. The outbreak has also reached North Kivu Province, the DRC capital Kinshasa, and Uganda's capital Kampala — indicating geographic spread beyond the original outbreak zone.
On May 18, 2026, the CDC implemented entry restrictions and enhanced airport screening for travelers arriving from DRC, Uganda, and South Sudan. A renewal order was issued June 21 for an additional 30 days, placing the current expiration around July 21.
Where the Risk Is Highest
The outbreak's risk zone remains centered on eastern DRC — specifically Ituri, North Kivu, and South Kivu provinces — and Uganda. The CDC recommends avoiding non-essential travel to these provinces and advises that travelers to other parts of DRC or Uganda take precautions to avoid Ebola exposure and monitor for symptoms for 21 days after leaving.
For Americans, the current outbreak poses a very low direct risk. The CDC has consistently assessed the likelihood of Bundibugyo virus spreading within the United States as low, given the country's public health infrastructure, hospital infection control capacity, and the virus's mechanism of transmission — which requires direct contact with bodily fluids of an infected person and does not spread through casual contact or the air.
All travelers who have recently been in DRC, Uganda, or South Sudan are being routed to designated U.S. airports for enhanced screening: Washington Dulles International Airport, John F. Kennedy International Airport (New York), Hartsfield-Jackson Atlanta International Airport, and George Bush Intercontinental Airport (Houston). Travelers are also subject to 21-day post-arrival symptom monitoring.
What Officials and Experts Say
Dr. Anne Ancia of the WHO acknowledged in her July 8 statement that the true case count remains incompletely understood due to surveillance gaps and the security situation. "We would like to say it is stabilising, but frankly, we cannot say it yet," she told reporters in Geneva, according to UN News.
The CDC's current situation assessment states: "The overall risk to the American public and travelers remains low." The agency notes that it is working with country offices in DRC and Uganda to provide technical support, including disease tracking, contact tracing, laboratory testing, and infection prevention and control.
The onset of the clinical trial of MBP134 and remdesivir is a meaningful development. No specific treatment has previously been licensed for Bundibugyo virus. If either compound shows clinical benefit in this trial, it would be the first evidence of an effective pharmacological treatment for this species of Ebola.
What the Evidence Shows — and What It Does Not
The reported death toll of 625 confirmed deaths in DRC reflects laboratory-confirmed cases. Given the surveillance gaps in conflict-affected areas acknowledged by the WHO, the actual death toll is likely higher than the confirmed figure.
The CDC's assessment that the risk of Bundibugyo virus reaching the United States is low is based on the biology of transmission, not on confirmed U.S. cases. It remains accurate as of July 10, 2026 — no cases have been detected in the U.S. However, the risk is not zero: an American missionary doctor contracted Bundibugyo virus in May 2026 while treating patients in DRC and was medically evacuated to Berlin's Charité Hospital for treatment. He subsequently recovered.
The absence of an approved vaccine is the most significant gap in the global response. The WHO has explicitly stated that cross-protection from Zaire-targeted Ebola vaccines cannot be assumed, and has recommended against their use in this outbreak absent stronger evidence.
MedicalDaily Evidence Check
- Outbreak declared: May 14–15, 2026 (DRC and Uganda)
- WHO PHEIC: Declared May 16, 2026
- Pathogen: Bundibugyo virus (Orthoebolavirus bundibugyoense)
- Confirmed deaths: 625 in DRC; 2 in Uganda (as of second week of July 2026)
- U.S. cases: Zero confirmed
- U.S. entry restriction: Active through approximately July 21, 2026 (30-day order issued June 21)
- Approved vaccine: None for Bundibugyo strain
- Treatment: Supportive only; clinical trial of MBP134 + remdesivir began July 2, 2026
- What readers should know: Risk to U.S. general public remains low; travelers to DRC, Uganda, South Sudan face screening requirements; anyone who develops fever, bleeding, or severe illness within 21 days of returning from the region should contact their local health department before seeking care
Who Faces the Greatest Risk?
In the United States, the groups with meaningful elevated risk from this outbreak are:
- People who have recently traveled to DRC, Uganda, or South Sudan — particularly those who visited medical facilities, burial ceremonies, or areas with known cases
- Healthcare workers with planned or recent assignments in the affected region — frontline medical workers face the highest occupational exposure risk
- Researchers and missionaries working in affected areas — as demonstrated by the case of the American physician evacuated in May
- Travelers who return from the region and develop fever, muscle aches, weakness, or unexplained bleeding within 21 days of their last possible exposure
For the vast majority of Americans who have not recently been in the affected region, the risk is negligible based on Bundibugyo virus's transmission biology.
Symptoms and Warning Signs to Watch For
Bundibugyo virus disease presents similarly to other forms of Ebola. Early symptoms — which appear two to 21 days after exposure — include:
- Sudden fever
- Severe headache
- Muscle pain and weakness
- Fatigue
- Sore throat
Later symptoms can include:
- Vomiting and diarrhea
- Rash
- Impaired kidney and liver function
- Internal and external bleeding (in some cases)
If you have traveled to DRC, Uganda, or South Sudan within the past 21 days and develop any of these symptoms, do not go directly to an emergency room. Call your local health department first. Public health authorities need to coordinate safe transport and isolation measures to protect healthcare workers and other patients. Mention your travel history to any clinician you contact.
What You Can Do Now
- Do not travel to Ituri, Nord-Kivu, or Sud-Kivu provinces in DRC. The CDC has issued a recommendation against non-essential travel to these areas.
- If you must travel to other parts of DRC or Uganda, monitor for symptoms for 21 days after returning. Avoid contact with sick people, animals, or materials that may have been contaminated with blood or bodily fluids.
- Travelers arriving from DRC, Uganda, or South Sudan should comply with enhanced entry screening requirements at designated U.S. airports and follow any monitoring instructions provided by public health officials on arrival.
- If you develop fever or illness within 21 days of returning, contact your local health department before visiting a healthcare facility.
- Check the CDC Ebola situation page for current travel recommendations and the status of entry restrictions after July 21.
Cost and Access: What Patients Should Know
Any person in the United States who is evaluated for suspected Ebola will be isolated and tested at no cost to them as part of public health response protocols. Ebola testing in the U.S. is coordinated through the CDC and state health departments and does not require prior authorization or insurance.
If a case were confirmed in the United States, treatment would be provided in a specially equipped biocontainment unit. The U.S. has ten such facilities nationally, all capable of providing high-level isolation and supportive care. The nearest facilities in major metro areas include Emory University Hospital in Atlanta, Nebraska Medical Center in Omaha, and the National Institutes of Health Clinical Center in Bethesda, Maryland.
For healthcare workers planning travel to the affected region, the CDC's health advisory for clinicians provides detailed infection prevention and control guidance.
What Happens Next
The CDC's current 30-day entry restriction order, issued June 21, 2026, expires around July 21, 2026. The CDC must determine whether the epidemiological situation in DRC and Uganda warrants extension. Given that the WHO cannot confirm the outbreak is stabilizing and that case counts continue to rise, extension appears likely — but the CDC has not yet announced its decision.
The clinical trial of MBP134 and remdesivir in DRC represents the first active therapeutic investigation for Bundibugyo virus disease. Early results from that trial may become available in the coming months. MedicalDaily will update this story as the July 21 policy deadline approaches and as further case data becomes available.
The Bottom Line
The 2026 Bundibugyo Ebola outbreak has now killed at least 625 people in DRC — the deadliest tally in any Bundibugyo virus outbreak on record. The WHO cannot yet confirm the outbreak is stabilizing. No approved vaccine or specific treatment exists, though a clinical trial of two experimental therapies is now underway. For most Americans, the risk from this outbreak remains low. For travelers who have recently returned from the affected region and develop any fever or unexplained illness within 21 days, the most important step is to contact your local health department before seeking care and to disclose your travel history immediately.
